Personal Care Formulations
US-2024245591-A1 · Jul 25, 2024 · US
Method of treating cancer
US12440505B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12440505-B2 |
| Application number | US-202117465921-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 3, 2021 |
| Priority date | Mar 5, 2019 |
| Publication date | Oct 14, 2025 |
| Grant date | Oct 14, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer comprising repeating a set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dosage such that 8 mg/kg or less of the compound represented by General Formula (I) is administered per dose, and irradiation to the patient immediately following the administration: where R 1 is an acyl residue from fatty acid, wherein a total dosage of the irradiation on a cancer is 10 Gy or more, and wherein the patient is a dog or cat. 2. The method according to claim 1 , comprising repeating the set at a frequency of once or less a day and once or more a month. 3. The method according to claim 1 , wherein the cancer is melanoma or lymphoma. 4. The method according to claim 1 , wherein the cancer is adenocarcinoma or squamous cell carcinoma. 5. The method according to claim 1 , wherein the dosage is such that the 0.5 mg/kg or more of the compound represented by General Formula (I) is administered per dose. 6. The method according to claim 1 , wherein R 1 is a stearoyl group. 7. The method according to claim 1 , wherein repeating the set of the administration and the irradiation leads to reduce the size of the cancer or eliminate the cancer. 8. The method according to claim 1 , wherein the total dosage of the irradiation on the cancer is 15 Gy or more. 9. The method according to claim 1 , wherein the set of the administration and the irradiation is repeated once or more every 2 weeks and repeated 10 times or less.
Assignees
Inventors
Classifications
Enhancing the effect of the particle by an injected agent or implanted device · CPC title
X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title
Antineoplastic agents · CPC title
- A61K31/7032Primary
attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides · CPC title
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12440505B2 cover?
- There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the i…
- Who is the assignee on this patent?
- M T 3 Inc, Univ Nihon, School Corporation Azabu Veterinary Medicine Educational Inst
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7032. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).